Group A streptococcus necrotizing fasciitis

Comprehensive Therapy

Volumn 26, Issue 2, 2000, Pages 73-81

  File, Thomas M ^a   Tan, James S ^b  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CLINDAMYCIN; IMMUNOGLOBULIN; PENICILLIN DERIVATIVE; PENICILLIN G;

ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL FEATURE; DEBRIDEMENT; DRUG CHOICE; HUMAN; NECROTIZING FASCIITIS; PATHOGENESIS; PATHOPHYSIOLOGY; STREPTOCOCCUS GROUP A;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CAUSALITY; DEBRIDEMENT; FASCIITIS, NECROTIZING; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PRACTICE GUIDELINES;

EID: 0033859247     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12019-000-0015-8     Document Type: Article

References (43)

1. Cellulitis and subcutaneous tissue infections
2. Streptococcal infections of skin and soft tissues
3. Bacteriology of necrotizing fasciitis
4. Invasive group A streptococcus infection
5. Molecular population genetic analysis of emerged bacterial pathogens: Selected insights
6. Serious Streptococcus pyogenes disease
7. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A
8. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome
9. The Working Group on Severe Streptococcal Infections Defining the group A streptococcal toxic shock syndrome: Rationale and consensus definition _rfsti JAMA
10. Current knowledge of type specific M antigens of group A streptococci
11. Changing epidemiology of group A streptococcal infection in the USA
12. A bacteriologic investigation of invasive streptococcal infections in Japan on the basis of serotypes, toxin production, and genomic DNA fingerprints
13. Invasive group A streptococcal infections in North Carolina: Epidemiology, clinical features, and genetic and serotype analysis of causative organisms
14. Familial transmission of a serious disease-producing group A streptococcus clone: Case reports and review
15. Clonal basis for resurgence of serious Streptococcus pyogenes disease in the 1980s
16. Genetic and phenotypic diversity among isolates of Streptococcus pyogenes from invasive infections
17. Characterization of a superantigen from a pathogenic strain of Streptococcus pyogenes
18. Group A streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure
19. Streptococcal toxic shock syndrome: Synthesis of tumor necrosis factor and interleukin-1 by monocytes stimulated with pyrogenic exotoxin A and streptolysin O
20. Group A streptococcal bacteremia: The role of tumor necrosis factor in shock and organ failure
21. Spread of serious disease-producing M3 clones of group A streptococcus among family members and health care workers
22. Molecular analysis of invasive M3 group A streptococcus clones from Akron and other geographic locations
23. Streptococcal toxic-shock syndrome: Spectrum of disease, pathogenesis, and new concepts in treatment
24. Necrotizing fasciitis due to group A streptococci in western Norway: Incidence and clinical features
25. Population-based surveillance for group A streptococcal necrotizing fasciitis: Clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases
26. Two clusters of invasive Streptococcus pyogenes infection in England
27. An outbreak of fatal nosocomial infections due to group A streptococcus on a medical ward
28. Could nonsteroidal anti-inflammatory drugs (NSAIDs) enhance the progression of bacterial infections to toxic shock syndrome
29. Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997
30. Magnetic resonance imaging in the early diagnosis of group A beta streptococcal necrotizing fasciitis: A case report
31. Determinants for mortality for necrotizing soft tissue infections
32. The Eagle effect revisited: Efficacy of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis
33. Experimental approach to the problem of treatment failure with penicillin: I: Group A streptococcal infection in mice
34. Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: An explanation for the inoculum effect
35. Effect of antibiotics on toxin production and viability of Clostridium perfringens
36. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin
37. Intravenous immunoglobulin therapy for toxic shock syndrome
38. Plasma from patients with severe group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal; super-antigen induced T-cell proliferation and cytokine expression
39. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: A comparative observational study
40. Cervical necrotizing fasciitis: Clinical manifestations and management
41. Hyperbaric oxygen therapy for necrotizing fasciitis reduces morality and the need for debridements
42. Necrotizing fasciitis: An indication for hyperbaric oxygen therapy
43. Aspects of pathogenesis of serious group A streptococcal infections in Sweden